IAP7 Rec'd PCT/PTO U 5 SEP 2006

Dkt. No. 69664-A-PCT-US/JPW/GAG

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Orna Mor, et al.

Serial No. : 10/562,177

International

Application No. : PCT/IL04/00565

Filed : June 24, 2004

For : DIAGNOSIS AND TREATMENT OF FIBROSIS

RELATED PATHOLOGY

1185 Avenue of the Americas New York, New York 10036 August 29, 2006

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. \$1.56, applicants direct the Examiner's attention to the following documents which are listed below and on Form PTO-1449, (Exhibit A).

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. \$1.97(b)(3) before the mailing of a first Office Action on the merits. Thus, this Information Disclosure Statement should be entered and considered.

The subject application is a §371 national stage of PCT International Application No. PCT/US04/00565. A copy of a May 24, 2006 International Search Report and a copy of the Written Opinion of the International Searching Authority for PCTUS04/00565 are attached hereto as (Exhibit B) and (Exhibit C), respectively:

Applicants: Orna Mor, et al.

Serial No.: 10/562,177 Filed: June 24, 2004

Page 2

- 1. Weber, K.T. (July 2000) "Fibrosis and Hypertensive Heart Disease." Curr. Opin. Cardiol. 15(4): 264-272 (Exhibit 1);
- 2. Kelly, Μ. et al. (May 2003) "Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis." Curr. Pharm. Des. 9 (9): 39-49 (Exhibit 2); and
- 3. Stausberg et al. (Dec 2002) "Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences." Proc. Of Nat. Acad. Of Sci. 99 (26): 16899-16903 (Exhibit 3).

Copies of documents numbers 1-3 are attached hereto as Exhibits 1-3, respectively.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

hereby certify that correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

White ofin P. No. 28,678

John A. White Registration No. 28,678 Attorney for Applicants Cooper & Dunham, LLP 1185 Avenue of the Americas New York, New York 10036 (212) 278-0400

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			Complete if Known	
			Application Number	10/562,177
STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	June 24, 2004
			First Named Inventor	Orna Mor
			Art Unit	
		Examiner Name		
Sheet	of		Attorney Docket Number	2094/69664-A-PCT-US/JPW/GAG

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	Weber, K.T. (July 2000) "Fibrosis and Hypertensive Heart Disease." Curr. Opin. Cardiol. 15(4): 264-272	
	2	Kelly, M. et al. (May 2003) "Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis." Curr. Pharm Des. 9(9): 39-49	
	3	Stausberg et al. (Dec 2002) "Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences." Proc. of Nat. Acad. of Sci. 99(26): 16899-16903	
			

C	
Examiner	Date
C:	Date
Signature	Considered
'EYAMINED: Initial if safe as	Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: